ReadyCell counts on a wide range of strategic partners with which the company has developed strong and long-lasting strategic partnerships. This consists in collaboration, joint initiatives, common projects and more.
NEXEL, Co., Ltd. is a bio-company that was incorporated in 2012 with proprietary stem cell technologies and cutting-edge techniques. They manufacture “more accurate, faster and easier” products from stem cells to develop more efficient tools for new drug discovery and incurable diseases. Additionally, they have discovered candidate proteins effective for liver fibrosis and cirrhosis. Their philosophy is to make a better place by supporting innovative research around the globe by providing a high quality of stem cell-derived cell products.
Leitat is a private technical institute with more than 110 years of experience in industrial innovation processes. It transforms technological and scientific results into economic and competitive value for its clients and collaborating entities. Over 1500 customers benefit from its talent, creativity and strong commitment. It brings knowledge and innovation to its customers through applied research and technical testing in the fields of chemistry, energy, environment, materials, engineering and life sciences. It relies upon its 240 highly skilled team members who deliver flexible solutions to face any industrial challenge.
ACCIÓ is the public agency for the competitiveness of the Catalan government. Its objective is to boost the competitiveness and growth of the Catalan businesses through the promotion of innovation, business internationalization and the attraction of investments. The agency accompanies and advises foreign companies during all phases of their projects, when looking for partners, the most competitive suppliers or the technology they need to establish in Catalonia. Currently, ACCIÓ accounts with a network of 40 foreign offices worldwide and seven branches throughout Catalonia. It collaborates with local and international business entities to add synergies and ensure that the Catalan company has a broader range of tools to grow in competitiveness.
The Netherlands Cancer Institute was established on October 10, 1913. The founders wanted to create a cancer institute ‘where patients suffering from malignant growths could be treated adequately and where cancer and related diseases could be studied’. Nowadays, The Institute accommodates approximately 650 scientists and scientific support personnel. The Antoni van Leeuwenhoek Hospital has 185 medical specialists, 180 beds, an out-patients clinic with around 106,000 visits, 12 operating theaters and 11 irradiation units for radiotherapy.